Re: Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, et al. Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab plus Olaparib Versus Abiraterone or Enzalutamide. EurUrol Oncol. In press. https://doi.org/10.1016/j.euo.2025.04.018.

IF 9.3 1区医学 Q1 ONCOLOGY

European urology oncology Pub Date : 2025-10-21 DOI:10.1016/j.euo.2025.07.017

Isabel Heidegger

引用次数: 0

回复：Niven Mehra， Emmanuel S. Antonarakis， Se Hoon Park等。KEYLYNK-010患者报告的结果：派姆单抗联合奥拉帕尼vs阿比特龙或恩杂鲁胺。EurUrol杂志。在出版社。https://doi.org/10.1016/j.euo.2025.04.018。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology oncology Multiple-

CiteScore

15.50

自引率

2.40%

发文量

128

审稿时长

20 days

期刊介绍： Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format